S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54

Bio-Techne Stock Forecast, Price & News

-7.33 (-2.07%)
(As of 06/28/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
179,150 shs
Average Volume
265,963 shs
Market Capitalization
$13.58 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock Forecast (MarketRank)

Overall MarketRank

2.89 out of 5 stars

Medical Sector

33rd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

2nd out of 217 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 1.7Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
Bio-Techne logo

About Bio-Techne (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Life Sciences Tools & Services
Current Symbol
Year Founded

Company Calendar

Last Earnings
Ex-Dividend for 5/27 Dividend
Dividend Payable
Fiscal Year End
Next Earnings (Estimated)

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$140.41 million
Pretax Margin


Sales & Book Value

Annual Sales
$931.03 million
Cash Flow
$8.06 per share
Book Value
$40.40 per share


Free Float
Market Cap
$13.58 billion

Social Links

Bio-Techne Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Bio-Techne stock.
View analyst ratings for Bio-Techne
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2022?

5 Wall Street research analysts have issued twelve-month price targets for Bio-Techne's stock. Their TECH stock forecasts range from $370.00 to $575.00. On average, they predict Bio-Techne's share price to reach $504.17 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts' price targets for Bio-Techne
or view top-rated stocks among Wall Street analysts.

How has Bio-Techne's stock performed in 2022?

Bio-Techne's stock was trading at $517.34 at the beginning of 2022. Since then, TECH shares have decreased by 33.1% and is now trading at $346.01.
View the best growth stocks for 2022 here

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Bio-Techne

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) released its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported $1.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.21. The biotechnology company earned $290.40 million during the quarter, compared to analysts' expectations of $279.27 million. Bio-Techne had a trailing twelve-month return on equity of 16.82% and a net margin of 20.95%. Bio-Techne's revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.61 earnings per share.
View Bio-Techne's earnings history

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Thursday, May 5th. Investors of record on Monday, May 16th will be given a dividend of $0.32 per share on Friday, May 27th. This represents a $1.28 annualized dividend and a dividend yield of 0.37%. The ex-dividend date is Friday, May 13th.
View Bio-Techne's dividend history

Is Bio-Techne a good dividend stock?

Bio-Techne(NASDAQ:TECH) pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.36%. The dividend payout ratio of Bio-Techne is 23.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.37% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.33%), BlackRock Inc. (11.21%), State Street Corp (4.07%), Neuberger Berman Group LLC (2.74%), Ownership Capital B.V. (2.14%) and Winslow Capital Management LLC (1.87%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne

Which institutional investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, William Blair Investment Management LLC, Artemis Investment Management LLP, Goldman Sachs Group Inc., Ownership Capital B.V., Candriam Luxembourg S.C.A., Sandler Capital Management, and Panagora Asset Management Inc.. Company insiders that have sold Bio-Techne company stock in the last two years include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, and Roeland Nusse.
View insider buying and selling activity for Bio-Techne
or view top insider-selling stocks.

Which institutional investors are buying Bio-Techne stock?

TECH stock was purchased by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Mackenzie Financial Corp, Assenagon Asset Management S.A., Winslow Capital Management LLC, Wellington Management Group LLP, Bank of New York Mellon Corp, BlackRock Inc., and Champlain Investment Partners LLC.
View insider buying and selling activity for Bio-Techne
or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $346.01.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $13.58 billion and generates $931.03 million in revenue each year. The biotechnology company earns $140.41 million in net income (profit) each year or $5.48 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,600 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for Bio-Techne is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at [email protected], or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.